Dernières nouvelles pour Dare Bioscience (NASDAQ:DARE) Stock

DARE BIOSCIENCE INC

Dare Bioscience

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Simulations Plus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) shares declined on Tuesday following the release of its third-quarter 2025 earnings report.
The company reported sales of $20.4 million, representing a 10% year-over-year increase, but this fell short of the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus estimate of $20.9 million</a>.
This miss followed preliminary third-quarter sales figures released in June, which were already lower than expectations at $19 million to $20 million, compared to a consensus of $22.78 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44764201/whats-going-on-with-charles-river-certara-simulations-plus-stocks-on-friday" rel="noreferrer noopener">What&#8217;s Going On With Charles River, Certara, Simulations Plus Stocks On Friday?</a>
Despite the revenue miss, Simulations Plus reported adjusted earnings of 45 cents per share, compared to <a href="https://www.benzinga.com/pressreleases/25/07/b46403848/simulations-plus-reports-third-quarter-fiscal-2025-financial-results" target="_blank" rel="noreferrer noopener">27 cents a year ago</a>.
Revenue breakdown showed a 6% increase in software revenue to $12.6 million and a 17% increase in services revenue to $7.7 million. The company&#8217;s gross profit stood at $13.0 million, achieving a 64% margin.
However, the quarter saw a substantial net loss of $67.3 million, resulting in a loss per share of $3.35. This was primarily due to a non-cash impairment charge of $77.2 million, contrasting sharply with a net income of $3.1 million and diluted EPS of $0.15 in the prior year.
Adjusted EBITDA was $7.4 million, representing 37% of total revenue, up from $5.6 million (30% of total revenue) in the same period last year.
Looking ahead, Simulations Plus revised its fiscal 2025 adjusted earnings guidance to $0.93 to $1.06, down from the previous <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44635451/simulations-plus-reports-second-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">guidance of $1.07 to $1.20</a>.
Similarly, the company&#8217;s <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/06/45912081/simulations-plus-slashes-guidance-amid-biotech-spending-cuts-analyst-expresses-doubt" rel="noreferrer noopener">fiscal 2025 sales forecast</a> was adjusted in June to $76 million to $80 million, a reduction from the prior guidance of $90 million to $93 million and below the consensus of $82.9 million.
The anticipated adjusted EBITDA margin for fiscal 2025 also saw a downward revision, now expected to be between 23% and 27%, compared to the earlier guidance of 31% to 33%.
In June, Simulations Plus initiated a restructuring of its operations, including <a target="_blank" href="https://www.benzinga.com/secfilings/25/06/45718737/simulations-plus-inc-general-corporate-statement-form8" rel="noreferrer noopener">workforce reductions</a> and cost-cutting measures, aimed at improving operational efficiency and reducing expenses.
William Blair analysts noted that the company&#8217;s outlook remains unchanged since June. They attribute the ongoing cautious spending by biopharma clients to uncertainties surrounding future funding, drug pricing, and potential tariffs, leading to budget cuts, project cancellations, and work postponements.
Analyst Max Smock highlighted, &#8220;While the software business remains somewhat resilient (expectation for 5% to 9% organic segment growth in fiscal 2025), we have begun to see some signs of potential softening as we head into fiscal 2026&#8230;&#8221;
In response to the challenging market, KeyBanc downgraded Simulations Plus from Overweight to Sector Weight. Analyst Scott Schoenhaus commented, &#8220;While we believe these challenges affect SLP more sharply given its customer concentration and biotech exposure, we also thought there would be opportunities with the most recent Proficiency acquisition that gave us hope that organic revenue growth could re-accelerate toward high-single digits next year (FY26) off easier comps.&#8221;
KeyBanc anticipates continued weak customer demand in the near to mid-term, with no clear signs of a biotech market rebound. This makes predicting a recovery difficult and a higher valuation hard to justify, prompting the firm to significantly cut its estimates and lower its valuation target to account for these risks and uncertainties.
Price Action: SLP stock is trading lower by 25% to $13.10 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46422474/polymarket-home-free-as-trump-led-doj-closes-biden-initiated-probes" target="_blank" rel="noreferrer noopener">Polymarket Home Free As Trump-Led DOJ Closes Biden-Initiated Probes</a></li>
</ul>

Analyst Color

Earnings

News

Guidance

Downgrades

Health Care

Analyst Ratings

Movers

Trading Ideas

General

Simulations Plus Sees Weaker Demand Persist, Outlook Softens

Rumors

QBTS

Watching D-Wave Quantum; Traders Circulate Popular Newsletter Buys Stock

Oppenheimer analyst Kristen Owen maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Outperform and raises the price target from $63 to $65.

Price Target

Oppenheimer Maintains Outperform on Nutrien, Raises Price Target to $65

Oppenheimer analyst Owen Lau maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $96 to $101.

NDAQ

Oppenheimer Maintains Outperform on Nasdaq, Raises Price Target to $101

Market Vectors Rare Earth/Strategic Metals Etf

REMX

Reuters Cites U.S. Defense Official Saying Pentagon's Investment In MP Materials 'Will Ensure A Near-term Market' For Rare Earths Production, Processing; Pentagon's Looking Forward To Continue Working With Companies Across Rare Earths Supply Chain To Ensure 'secure And Resilient Supply' For Country

Oppenheimer analyst Rick Schafer maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Outperform and raises the price target from $175 to $200.

NVDA

Oppenheimer Maintains Outperform on NVIDIA, Raises Price Target to $200

The U.S. stock market has just completed one of its strongest three-month runs in history, with the S&amp;P 500 soaring 26% between April 9 and July 10, a pace of gains rarely seen. While historical analogues suggest further upside, signs of overheated investor sentiment are starting <a href="https://www.benzinga.com/topic/expert-ideas">to worry market watchers.</a>
<h3 class="wp-block-heading">What Does History Say About Similar Rallies?</h3>
This is only the sixth time since 1950 that the S&amp;P 500 – as tracked by the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) – has gained at least 25% over a three-month stretch. In every previous instance, the index delivered strong returns over the next year.
According to data from Carson Investment Research, the median forward 12-month return following such rallies is 18.5%, and all five historical cases saw positive returns over the next 12 months.
Forward returns over 3 and 6 months also had a 100% success rate, with median gains of 9.7% and 15.1%, respectively.
Yet, it&#8217;s worth noting that short-term pullbacks often occurred: in four out of five previous rallies, the index experienced a mild 1-month decline or pause.
For context, the average 12-month return for all years since 1950 is 9.2%, making these post-surge periods more than twice as strong on average.
<h4 class="wp-block-heading">S&amp;P 500 Forward Returns After 3-Month Gains of 25% or More (1950–2025)</h4>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Date</th>
<th>3-Month Gain</th>
<th>1-Month Return</th>
<th>3-Month Return</th>
<th>6-Month Return</th>
<th>12-Month Return</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/07/1975</td>
<td>27.5%</td>
<td>-3.9%</td>
<td>9.7%</td>
<td>1.6%</td>
<td>17.6%</td>
</tr>
<tr>
<td>10/21/1982</td>
<td>25.1%</td>
<td>-1.5%</td>
<td>5.2%</td>
<td>15.1%</td>
<td>19.9%</td>
</tr>
<tr>
<td>01/05/1999</td>
<td>25.9%</td>
<td>0.3%</td>
<td>6.6%</td>
<td>12.1%</td>
<td>12.4%</td>
</tr>
<tr>
<td>05/29/2009</td>
<td>25.0%</td>
<td>0.9%</td>
<td>12.2%</td>
<td>20.8%</td>
<td>18.5%</td>
</tr>
<tr>
<td>06/15/2020</td>
<td>28.5%</td>
<td>5.2%</td>
<td>10.3%</td>
<td>19.5%</td>
<td>38.5%</td>
</tr>
<tr>
<td>07/10/2025</td>
<td>26.0%</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Carson Investment Research</figcaption></figure>
<h3 class="wp-block-heading">Fund Managers Grow Aggressively Bullish</h3>
The latest Bank of America Global Fund Manager Survey, released July 15, confirms a dramatic shift in sentiment. 
Fund managers report their most bullish outlook since February 2025, fueled by a &#8220;record surge in risk appetite&#8221; and optimism around profits.
The survey shows:
<ul class="wp-block-list">
<li>Cash levels have dropped to 3.9%, triggering BofA's contrarian &#8220;sell signal.&#8221;</li>
<li>A net 59% of managers say a recession is unlikely, reversing April&#8217;s 42% who believed one was probable.</li>
<li>86% expect either a soft or no landing, while just 9% forecast a hard landing.</li>
</ul>
These metrics, while bullish, are flashing some red lights. 
BofA described the sentiment as "toppy," and warned that the most vulnerable positions are now in short U.S. dollar, long U.S. tech, and long EU banks — all consensus trades that could unwind if macro conditions shift.
"Greed is always harder to reverse than fear," Bank of America&#8217;s chief investment strategist Michael Hartnett said. 
<h3 class="wp-block-heading">What Could Derail The Rally?</h3>
Any upside surprises in inflation, earnings disappointments in the second quarter, or sudden spikes in bond yields could pressure this crowded long positioning, especially in tech and European banks, according to the survey. 
The S&amp;P 500's explosive 26% rally over three months puts it in rare historical records, and the data suggests more gains could lie ahead. 
Every similar surge since 1950 delivered positive returns over the following year, with median 12-month gains clocking in at 18.5% — more than double the historical average.
The rally has been powerful, and momentum is still on the bulls' side. But if inflation runs hot, earnings disappoint, or bond yields climb, the &#8220;toppy&#8221; sentiment flagged by Bank of America could quickly turn from tailwind to trap.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46402633/sp500-record-highs-narrow-breadth-2025">S&amp;P 500 Record Highs Hide A Fracture Unseen In Decades </a></li>
</ul>
Photo: Phongphan On Shutterstock.com

S&P 500 Defies Odds With Rare Rally — But 'Toppy' Sentiment Creeps In

Oppenheimer analyst Rick Schafer maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Outperform and raises the price target from $700 to $800.

MPWR

Oppenheimer Maintains Outperform on Monolithic Power Systems, Raises Price Target to $800

Tesla, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) top sales leader in North America has left the company, marking another significant executive exit as the automaker grapples with a sharp <a href="https://www.benzinga.com/markets/tech/25/07/46239731/elon-musks-tesla-sales-surge-3-7-in-china-as-other-markets-cool">decline in sales. </a>
The Details: Troy Jones, who served as vice president of sales, service and delivery in Tesla's largest market, departed after a 15-year tenure, <a href="https://www.wsj.com/business/autos/tesla-troy-jones-north-american-sales-leaves-b2ac616d">according</a> to the Wall Street Journal.
This latest executive departure follows the recent exit of Omead Afshar, a close advisor to CEO Elon Musk. Afshar, who was promoted less than a year ago to oversee all sales and manufacturing operations in North America and Europe, left the company less than a month ago.
Read Next: <a href="https://www.benzinga.com/markets/tech/25/07/46422009/rare-earth-royalty-meet-the-power-players-shaping-the-industry?utm_source=articleShare">Rare Earth Royalty: Meet The Power Players Shaping The Industry</a>
Other notable departures include Jenna Ferrua, Tesla's director of human resources for North America, who left in June. 
Earlier in the year, Milan Kovac, a vice president of engineering responsible for the development of Tesla's Optimus humanoid robot, also exited the company. The Optimus project is a key part of Musk's vision to transform Tesla into a leader in robotics and artificial intelligence.
<h1 class="wp-block-heading">Company Response and Recent Moves</h1>
To counteract falling sales and increased competition, Tesla has introduced several new vehicle updates and offered low-cost financing options to attract buyers. Recent product launches include:
<ul class="wp-block-list">
<li>A refreshed Model Y midsize SUV in March</li>
<li>A more affordable, simplified version of the Cybertruck in April</li>
<li>Updated versions of the Model S and Model X luxury vehicles in June</li>
</ul>
Despite concerns from Wall Street about declining sales and shrinking profit margins, Tesla's leadership has emphasized the long-term potential of its investments in autonomous driving technology — branded as Full Self-Driving — and the Optimus robot.
Why It Matters: Tesla recorded a 9.09% year-over-year increase in <a href="https://www.benzinga.com/markets/tech/25/07/46239731/elon-musks-tesla-sales-surge-3-7-in-china-as-other-markets-cool">Model Y sales</a> in China during June, reflecting a strong rebound that aligned with the company's better-than-expected second-quarter deliveries. 
According to data from CnEVPost, Tesla sold 44,848 Model Y units in China during the month, recovering from two consecutive months of declining sales. 
Tesla also experienced growth in the U.K. market, where it saw a 12% increase in sales as the company delivered 7,189 vehicles during the second quarter of 2025.
This comes as Musk assumed direct oversight of Tesla&#8217;s sales operations in Europe and the U.S. following the departure of Afshar. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46374434/joby-aviation-stock-goes-vertical-as-secret-massive-drone-achieves-9-hour-flight?utm_source=articleShare">Joby Aviation Stock Goes Vertical As Secret, Massive Drone Achieves 9-Hour Flight</a></li>
</ul>
Image: Shutterstock

Large Cap

Management

Tech

TSLA

Tesla's Sales Turmoil Deepens With North America Sales Chief's Exit

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is expected to post a <a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">52% jump in</a> second-quarter 2025 profit, driven by booming AI demand. However, it faces pressure from potential U.S. tariffs and a sharply stronger Taiwan dollar.
IDC&#8217;s group VP Mario Morales told Reuters the foundry sector could grow 17–18% in 2025, but Taiwan Semiconductor&#8217;s moat may push its sales growth closer to 30%.
According to LSEG SmartEstimate, the company is forecast to report 377.4 billion New Taiwan dollars ($12.9 billion) in net profit for the quarter. If it exceeds 374.68 billion New Taiwan dollars, that would mark its highest-ever quarterly profit and its sixth straight quarter of earnings growth.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46283410/taiwan-semiconductor-shifts-focus-100-billion-usa-expansion" rel="noreferrer noopener">Taiwan Semiconductor Shifts Focus To $100 Billion USA Expansion Instead Of Japan</a>
Taiwan Semiconductor has already guided for a <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46338109/tsmc-reports-solid-half-year-revenue-june-sees-monthly-decline" rel="noreferrer noopener">38.6% jump in</a> second-quarter revenue.
The stock traded higher on Tuesday in solidarity with its semiconductor peers after reports indicated <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46412125/trumps-latest-move-on-ai-and-china-propels-chip-stocks" rel="noreferrer noopener">the Trump administration&#8217;s plans</a> to unveil a $70 billion tech and energy investment plan in Pennsylvania and that the U.S. lifted chip export curbs to China.
TSMC stock surged nearly 20% year-to-date, topping the PHLX Semiconductor Index&#8217;s 16% as a key supplier of Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
<h2 class="wp-block-heading">Profit Headwinds</h2>
However, the company faces external headwinds. In April, the U.S. threatened Taiwan with a 32% reciprocal tariff, and President Donald Trump recently indicated new chip tariffs could arrive soon.
On the currency front, the Taiwan dollar has strengthened 12% against the U.S. dollar this year. Taiwan Semiconductor has noted that a 1% rise in the Taiwan dollar typically reduces its gross margin by 0.4 percentage points.
On the management front, Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46387337/taiwan-semiconductors-top-supply-chain-executive-exits" rel="noreferrer noopener">announced Friday that</a> Vanessa Lee, head of materials management, resigned for personal reasons. Senior Vice President and Deputy Co-COO Cliff Hou will immediately assume leadership of his materials management division.
Lee joined Taiwan Semiconductor in 2022 and became vice president in August 2023. She developed forecasting systems and supply chain performance tools, earning credit for helping the chipmaker manage disruptions during the 2020 pandemic.
In March, the company committed $100 billion to expand U.S. operations on top of the $65 billion already pledged for three chip plants in Arizona, announced alongside Trump at the White House.
Taiwan Semiconductor will report second-quarter earnings Thursday and issue third-quarter guidance.
Price Action:&nbsp;TSM stock is trading higher by 3.30% to $236.22 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46363788/asml-drops-us-diversity-goals-under-trumps-watch" target="_blank" rel="noreferrer noopener">ASML Drops US Diversity Goals Under Trump&#8217;s Watch</a></li>
</ul>
Photo by Jack Hong via Shutterstock

Media

AAPL

What To Expect From Taiwan Semiconductor Q2 Performance?

<a href="https://www.bloomberg.com/news/articles/2025-07-15/nato-chief-warns-china-india-and-brazil-over-russia-links">https://www.bloomberg.com/news/articles/2025-07-15/nato-chief-warns-china-india-and-brazil-over-russia-links</a>

Macro Notification

Politics

INDA

'NATO Chief Warns China, India and Brazil Over Russia Links'- Bloomberg

Oppenheimer analyst Kristen Owen maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Outperform and raises the price target from $555 to $560.

Oppenheimer Maintains Outperform on Deere, Raises Price Target to $560

Oppenheimer analyst Kristen Owen maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Outperform and raises the price target from $75 to $87.

CTVA

Oppenheimer Maintains Outperform on Corteva, Raises Price Target to $87

Oppenheimer analyst Kristen Owen maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Outperform and raises the price target from $15 to $16.

Oppenheimer Maintains Outperform on CNH Industrial, Raises Price Target to $16

CIBC analyst Cosmos Chiu maintains Alamos Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AGI#TSX">AGI</a>) with a Outperformer and raises the price target from C$48 to C$55.

TSX:AGI

CIBC Maintains Outperformer on Alamos Gold, Raises Price Target to C$55

Oppenheimer analyst Owen Lau maintains Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) with a Outperform and raises the price target from $249 to $253.

CBOE

Oppenheimer Maintains Outperform on Cboe Global Markets, Raises Price Target to $253

<a href="https://ofac.treasury.gov/recent-actions/20250715">https://ofac.treasury.gov/recent-actions/20250715</a>

IBKR

Settlement Agreement Between The U.S. Department Of the Treasury's Office Of Foreign Assets Control And Interactive Brokers LLC

Oppenheimer analyst Rick Schafer maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Outperform and raises the price target from $265 to $305.

AVGO

Oppenheimer Maintains Outperform on Broadcom, Raises Price Target to $305

CIBC analyst Anita Soni maintains Agnico Eagle Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>) with a Outperformer and raises the price target from $134 to $165.

CIBC Maintains Outperformer on Agnico Eagle Mines, Raises Price Target to $165

Oppenheimer analyst Kristen Owen maintains Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) with a Outperform and lowers the price target from $7 to $6.

BIOX

Oppenheimer Maintains Outperform on Bioceres Crop Solutions, Lowers Price Target to $6

Press Releases

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré's DARE to PLAY Sildenafil Cream

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Comments

Dare Bioscience

Actualités

Dernières nouvelles pour Dare Bioscience (NASDAQ:DARE) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL